This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Incorrect Abstract.—In the abstracts that were published in the April Archives (36:251-252, 1979), the abstract printed for Nall et al on page 251 is incorrect. The abstract should read
Acetylcholine Receptor Antibodies in Myasthenia Gravis J. Nall; P. Kornfeld; T. Mittag; A. Bender; S. H. Horowitz; A. E. Papatestas; H. Gross; G. Genkins
Dysfunction of neuromuscular transmission in myasthenia gravis is associated with a decrease in the number of acetylcholine receptors at the myoneural junction. This loss of receptors is ascribed to immunological alteration. To date, most patients with clinical myasthenia gravis have been reported to have serum antibodies to acetylcholine receptors. However, the clinical correlation with antibody titer is unclear.
The serums of 150 patients with all clinical forms of myasthenia gravis were analyzed for antibody to acetylcholine receptors. A radioimmunoassay using denervated rat muscle receptor was used. Titers varied widely within clinical groups. No correlation with sex, age
CORRECTION. Arch Neurol. 1979;36(8):500. doi:10.1001/archneur.1979.00500440070013
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: